Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABMIL:1GETI 53 1-Year ROIIC % is 72.17 as of Jun. 2026. GuruFocus rates MIL:1GETI with a GF Score™ of 53/100 and a GF Value™ of €17.70 (Fairly Valued). The stock has 10 warning signs investors should review. Among 820 Medical Devices & Instruments companies, Getinge AB ranks better than 83.54% on this metric.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Getinge AB's 1-Year ROIIC % for the quarter that ended in Jun. 2026 was 72.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Getinge AB's 1-Year ROIIC % or its related term are showing as below:
MIL:1GETI's 1-Year ROIIC % is ranked better than 83.54% of 820
companies
in the Medical Devices & Instruments industry
Industry Median: 0.905
vs MIL:1GETI: 72.17
Getinge AB (MIL:1GETI) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Getinge AB 1-Year ROIIC % Related Terms
Getinge AB 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Getinge AB's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1GETI vs ABT, SYK, MDT: 1-Year ROIIC % Comparison
For the Medical Devices subindustry, Getinge AB's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB 1-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Getinge AB's 1-Year ROIIC % falls into.
Getinge AB's 1-Year ROIIC % for the quarter that ended in Jun. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( 296.4935 (Jun. 2026) - 233.6599 (Jun. 2025) )
/
( 4855.436 (Jun. 2026) - 4756.414 (Jun. 2025) )
=
62.8336
/
99.022
=
63.45%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Getinge AB (MIL:1GETI) has a 1-Year ROIIC % of 72.17 as of Jun. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Getinge AB and its competitors. According to the industry distribution chart, Getinge AB ranks #135 out of 820 companies in the Medical Devices & Instruments industry, placing it in the top 16.5%.
Is Getinge AB's 1-Year ROIIC % too high?
Getinge AB's current 1-Year ROIIC % is 72.17. The Medical Devices & Instruments industry median 1-Year ROIIC % is 0.91. Getinge AB's value of 72.17 is 7874.6% above this industry median. Based on the distribution chart, Getinge AB ranks #135 out of 820 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getinge AB has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's 1-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #135 out of 820 companies for 1-Year ROIIC %. This places Getinge AB in the top 17% of its industry — outperforming the majority of peers. The industry median 1-Year ROIIC % is 0.91. Getinge AB's value of 72.17 is 7874.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Medical Devices & Instruments company?
The median 1-Year ROIIC % among Medical Devices & Instruments companies is 0.91, based on 820 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current 1-Year ROIIC % of 72.17 is 7874.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median 1-Year ROIIC % is 0.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current 1-Year ROIIC % is 72.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (MIL:1GETI) is currently considered Fairly Valued. The stock's GF Value™ is €17.70, compared to a current price of €17.10 — trading 3.4% below its estimated fair value. The current 1-Year ROIIC % is 72.17 and 7874.6% above the Medical Devices & Instruments industry median of 0.91. Getinge AB's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Getinge AB (MIL:1GETI), the current 1-Year ROIIC % is 72.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (MIL:1GETI) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be undervalued.
The current stock price of €17.10 is trading 3.4% below its estimated GF Value™ of €17.70.
GuruFocus considers Getinge AB to be Fairly Valued.
Key valuation signals for MIL:1GETI:
1-Year ROIIC %: 72.17
GF Value™: €17.70 vs. price of €17.10 (3.4% below fair value)
Industry Position: 7874.6% above the Medical Devices & Instruments median (#135 of 820)
No single metric tells the full story. See the MIL:1GETI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
53GF Score
Get the complete analysis for MIL:1GETI
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1GETI has been successfully added to your 
